ISRAEL BENDIT

(Fonte: Lattes)
Índice h a partir de 2011
15
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder

Resultados de Busca

Agora exibindo 1 - 10 de 75
  • bookPart
    Biologia molecular dos tumores da infância
    (2013) BENDIT, Israel; SOUZA, Ana Carolina Mamana Fernandes de
  • conferenceObject
    Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
    (2019) HUGHES, Timothy P.; SAGLIO, Giuseppe; LARSON, Richard A.; KANTARJIAN, Hagop M.; KIM, Dong-Wook; ISSARAGRISIL, Surapol; COUTRE, Philipp Le; ETIENNE, Gabriel; BOQUIMPANI, Carla; CLARK, Richard E.; DUBRUILLE, Viviane; FLINN, Ian W.; KYRCZ-KRZEMIEN, Slawomira; MEDRAS, Ewa; ZANICHELLI, Maria; BENDIT, Israel; SONDHI, Manu; TITORENKO, Ksenia; NOURRY-BOULOT, Claire; AIMONE, Paola; HOCHHAUS, Andreas
  • article 44 Citação(ões) na Scopus
    Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale
    (2013) WHITE, Helen E.; HEDGES, John; BENDIT, Israel; BRANFORD, Susan; COLOMER, Dolors; HOCHHAUS, Andreas; HUGHES, Timothy; KAMEL-REID, Suzanne; KIM, Dong-Wook; MODUR, Vijay; MUELLER, Martin C.; PAGNANO, Katia B.; PANE, Fabrizio; RADICH, Jerry; CROSS, Nicholas C. P.; LABOURIER, Emmanuel
    BACKGROUND: Current guidelines for managing Philadelphia-positive chronic myeloid leukemia include monitoring the expression of the BCR-ABL1 (breakpoint cluster region/c-abl oncogene 1, nonreceptor tyrosine kinase) fusion gene by quantitative reverse-transcription PCR (RT-qPCR). Our goal was to establish and validate reference panels to mitigate the interlaboratory imprecision of quantitative BCR-ABL1 measurements and to facilitate global standardization on the international scale (IS). METHODS: Four-level secondary reference panels were manufactured under controlled and validated processes with synthetic Armored RNA Quant molecules (Asuragen) calibrated to reference standards from the WHO and the NIST. Performance was evaluated in IS reference laboratories and with non-IS-standardized RT-qPCR methods. RESULTS: For most methods, percent ratios for BCR-ABL1 e13a2 and e14a2 relative to ABL1 or BCR were robust at 4 different levels and linear over 3 logarithms, from 10% to 0.01% on the IS. The intraassay and interassay imprecision was <2-fold overall. Performance was stable across 3 consecutive lots, in multiple laboratories, and over a period of 18 months to date. International field trials demonstrated the commutability of the reagents and their accurate alignment to the IS within the intra-and interlaboratory imprecision of IS-standardized methods. CONCLUSIONS: The synthetic calibrator panels are robust, reproducibly manufactured, analytically calibrated to the WHO primary standards, and compatible with most BCR-ABL1 RT-qPCR assay designs. The broad availability of secondary reference reagents will further facilitate interlaboratory comparative studies and independent quality assessment programs, which are of paramount importance for worldwide standardization of BCR-ABL1 monitoring results and the optimization of current and new therapeutic approaches for chronic myeloid leukemia. (C) 2013 American Association for Clinical Chemistry
  • conferenceObject
    Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country
    (2020) BRANDAO, Antonio Adolfo Guerra Soares; FATOBENE, Giancarlo; ABDO, Andre; LAGE, Luis Alberto De Padua Covas; BENDIT, Israel; NARDINELLI, Luciana; SIQUEIRA, Sheila Aparecida Coelho De; LEVY, Debora; PEREIRA, Juliana; REGO, Eduardo M.; ROCHA, Vanderson
  • article 5 Citação(ões) na Scopus
    MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial
    (2021) SEGURO, Fernanda S.; MACIEL, Felipe V. R.; SANTOS, Fernanda M.; ABDO, Andre N. R.; PEREIRA, Thales D. M.; NARDINELLI, Luciana; ROCHA, Vanderson; BENDIT, Israel
    Background: Treatment-free survival (TFS) in chronic myeloid leukemia (CML) is a new goal. This prospective study aims to evaluate imatinib discontinuation's feasibility and safety in patients with deep molecular response MR4 (BCR-ABL1 < 0.01 % IS). Methods: Study was approved by the ethical committee and registered at Clinicaltrials.gov (NCT03239886). Incluision criteria were: age >= 18y, chronic phase, first-line imatinib for 36 months, MR4 for 12 months, no previous transplant or resistance. Imatinib was resumed when two samples confirmed the loss of MMR. The primary endpoint was molecular recurrence-free survival (MRFS) at 24 months. Lymphocyte subpopulations were counted in peripheral blood before discontinuation. Results: 31 patients were included from Dec/2016 until Oct/2017. Median age was 54years, 58 % male, 58 % low Sokal, 65 % b3a2 transcripts, and 61 % were in MR4.5. Imatinib therapy's median time was 9.7y (3-14.9 y), median time of MR4 was 6.9y (1.6-10.3y). MRFS at 24 months was 55 % (95 % CI 39-75). Thirteen patients relapsed, 46 % after six months of discontinuation, and all patients recovered MMR. Median time to recover MMR was one month. MR4.5 was the only factor associated with MRFS. NK cells proportion at baseline was lower in patients with only MR4 who relapsed after discontinuation. Conclusion: With a median duration of sustained MR4 above five years, as recommended by most TKI discontinuation guidelines, the TFS was similar to previous studies. Only MR4.5 was associated with lower risk of relapse. Further studies are needed to evaluate whether patients with only MR4 and low NK cell levels are suitable for discontinuation.
  • article 5 Citação(ões) na Scopus
    Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (vol 35, 20-LEU-1554R, 2021)
    (2021) KANTARJIAN, Hagop M.; HUGHES, Timothy P.; LARSON, Richard A.; KIM, Dong-Wook; ISSARAGRISIL, Surapol; COUTRE, Philipp le; ETIENNE, Gabriel; BOQUIMPANI, Carla; PASQUINI, Ricardo; CLARK, Richard E.; DUBRUILLE, Viviane; FLINN, Ian W.; KYRCZ-KRZEMIEN, Slawomira; MEDRAS, Ewa; ZANICHELLI, Maria; BENDIT, Israel; CACCIATORE, Silvia; TITORENKO, Ksenia; AIMONE, Paola; SAGLIO, Giuseppe; HOCHHAUS, Andreas
  • article 523 Citação(ões) na Scopus
    The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
    (2013) ABBOUD, Camille; BERMAN, Ellin; COHEN, Adam; CORTES, Jorge; DEANGELO, Daniel; DEININGER, Michael; DEVINE, Steven; DRUKER, Brian; FATHI, Amir; JABBOUR, Elias; JAGASIA, Madan; KANTARJIAN, Hagop; KHOURY, Jean; LANEUVILLE, Pierre; LARSON, Richard; LIPTON, Jeffrey; MOORE, Joseph O.; MUGHAL, Tariq; O'BRIEN, Susan; PINILLA-IBARZ, Javier; QUINTAS-CARDAMA, Alfonso; RADICH, Jerald; REDDY, Vishnu; SCHIFFER, Charles; SHAH, Neil; SHAMI, Paul; SILVER, Richard T.; SNYDER, David; STONE, Richard; TALPAZ, Moshe; TEFFERI, Ayalew; ETTEN, Richard A. Van; WETZLER, Meir; ABRUZZESE, Elisabetta; APPERLEY, Jane; BRECCIA, Massimo; BYRNE, Jenny; CERVANTES, Francisco; CHELYSHEVA, Ekaterina; CLARK, R. E.; LAVALLADE, Hugues de; DYAGIL, Iryna; GAMBACORTI-PASSERINI, Carlo; GOLDMAN, John; HAZNEDAROGLU, Ibrahim; HJORTH-HANSEN, Henrik; HOLYOAKE, Tessa; HUNTLY, Brian; COUTRE, Philipp le; LOMAIA, Elza; MAHON, Francois-Xavier; MARIN-COSTA, David; MARTINELLI, Giovanni; MAYER, Jiri; MILOJKOVIC, Dragana; OLAVARRIA, Eduardo; PORKKA, Kimmo; RICHTER, Johan; ROUSSELOT, Philippe; SAGLIO, Giuseppe; SAYDAM, Guray; STENTOFT, Jesper; TURKINA, Anna; VIGNERI, Paolo; ZARITSKEY, Andrey; AGUAYO, Alvaro; AYALA, Manuel; BENDIT, Israel; BENGIO, Raquel Maria; BEST, Carlos; BULLORSKY, Eduardo; CERVERA, Eduardo; DESOUZA, Carmino; FANILLA, Ernesto; GOMEZ-ALMAGUER, David; HAMERSCHLAK, Nelson; LOPEZ, Jose; MAGARINOS, Alicia; MEILLON, Luis; MILONE, Jorge; MOIRAGHI, Beatriz; PASQUINI, Ricardo; PAVLOVSKY, Carolina; RUIZ-ARGUELLES, Guillermo J.; SPECTOR, Nelson; ARTHUR, Christopher; BROWETT, Peter; GRIGG, Andrew; HU, Jianda; HUANG, Xiao-jun; HUGHES, Tim; JIANG, Qian; JOOTAR, Saengsuree; KIM, Dong-Wook; MALHOTRA, Hemant; MALHOTRA, Pankaj; MATSUMURA, Itaru; MELO, Junia; OHNISHI, Kazunori; OHNO, Ryuzo; SAIKIA, Tapan; SCHWARER, Anthony P.; TAKAHASHI, Naoto; TAM, Constantine; TAUCHI, Tetsuzo; USUKI, Kensuke; WANG, Jianxiang; ABDEL-RAHMAN, Fawzi; ALJURF, Mahmoud Deeb Saeed; BAZARBACHI, Ali; YEHUDA, Dina Ben; CHAUDHRI, Naeem; DUROSINMI, Muheez; KAMEL, Hossam; LOUW, Vernon; FRANCISMATTI, Bassam; NAGLER, Arnon; RAANANI, Pia; SALEM, Ziad
    As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
  • article 21 Citação(ões) na Scopus
    Investigation of human parvovirus B19 occurrence and genetic variability in different leukaemia entities
    (2013) COSTA, A. C. da; BENDIT, I.; OLIVEIRA, A. C. S. de; KALLAS, E. G.; SABINO, E. C.; SANABANI, S. S.
    Human parvovirus B19V (B19V) has been associated with various haematological disorders, but data on its prevalence in leukaemia are scarce. In this cross-sectional study, we investigated patients in Sao Paulo, Brazil with leukaemia to determine the molecular frequency of B19 variants and characterize the viral genetic variability by partial and complete sequencing of the coding of non-structural protein 1 (NS1)/viral capsid proteins 1 and 2 (VP1/VP2). The presence of B19V infections was investigated by PCR amplification of the viral NS1 gene fragment and confirmed by sequencing analysis. The NS1/VP1/VP2 and partially larger gene fragments of the NS1-positive samples were determined by overlapping nested PCR and direct sequencing results. The B19V NS1 was detected in 40 (16%) of 249 bone marrow samples including 12/78 (15.4%) acute lymphoblastic leukaemia, 25/155 (16.1%) acute myeloid leukaemia and 3/16 (18.7%) chronic myeloid leukaemia samples. Of the 40 participants, 25 (62.5%) were infected with genotype 1a and 15 (37.5%) with genotype 3b. The phylogenetic analysis of other regions revealed that 12/40 (30%) of the patients with leukaemia were co-infected with genotypes 1a and 3b. In addition, a new B19V intergenotypic recombinant (1a/3b) and an NS1 non-recombinant genotype 1a were detected in one patient. Our findings demonstrated a relatively high prevalence of B19V monoinfections and dual infections and provide, for the first time, evidence of inter-genotypic recombination in adults with leukaemia that may contribute to the genetic diversity of B19V and may also be a source of new emerging viral strains with future implications for diagnosis, therapy and efficient vaccine development.
  • article 40 Citação(ões) na Scopus
    Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
    (2017) HUGHES, T. P.; LEBER, B.; CERVANTES, F.; SPECTOR, N.; PASQUINI, R.; CLEMENTINO, N. C. D.; SCHWARER, A. P.; DORLHIAC-LLACER, P. E.; MAHON, F-X; REA, D.; GUERCI-BRESLER, A.; KAMEL-REID, S.; BENDIT, I.; ACHARYA, S.; GLYNOS, T.; DALAL, D.; BRANFORD, S.; LIPTON, J. H.
  • article 6 Citação(ões) na Scopus
    Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012
    (2012) SOUZA, Carmino Antonio de; PAGNANO, Katia Borgia Barbosa; BENDIT, Israel; CONCHON, Monika; FREITAS, Carla Maria Boquimpani de Moura; COELHO, Arthur Moellmann; FUNKE, Vaneuza Araújo Moreira; BERNARDO, Wanderley Marques